Loading data…
Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.
$42.57M net loss for the year ended December 30, 2025. These are reported results, not a forecast or a stock recommendation.
Latest-filed standard financial facts · USD
Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.
Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.
| Reported period | Reported value | Filed | Source |
|---|---|---|---|
| January 1, 2025 – December 30, 2025 | $495,089,000 | March 26, 2026 | 10-K ↗ |
| January 3, 2024 – December 31, 2024 | $493,271,000 | March 26, 2026 | 10-K ↗ |
| January 4, 2023 – January 2, 2024 | $503,405,000 | March 26, 2026 | 10-K ↗ |
| December 29, 2021 – January 3, 2023 | $509,480,000 | March 7, 2025 | 10-K ↗ |
| December 30, 2020 – December 28, 2021 | $475,152,000 | March 8, 2024 | 10-K ↗ |
| January 1, 2020 – December 29, 2020 | $393,655,000 | March 9, 2023 | 10-K ↗ |
| January 2, 2019 – December 31, 2019 | $462,411,000 | February 24, 2022 | 10-K ↗ |
| January 3, 2018 – January 1, 2019 | $457,841,000 | February 26, 2021 | 10-K ↗ |
One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.
Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 15, 2026
Response SHA-256: 4e1fa08ad3c4ca979327cb33b1304110ce922283040633c423376b9e1c1a939b
Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.